
Erica Cai, PhD
Assistant Research Professor of Pediatrics
- Phone
- (317) 274-7999
- Address
-
BRTC (L3) Room 239
PENB
IN
Indianapolis, IN
Bio
Dr. Erica Cai is an Assistant Research Professor of Pediatrics at the Indiana University School of Medicine (IUSM). She is a faculty member of the Herman B. Wells Center for Pediatric Research and the Indiana Center for Diabetes and Metabolic Diseases (CDMD). Dr. Cai obtained her bachelor’s degree in Medical Technology from Taipei Medical University and her master’s degree in Biochemistry and Molecular Biology from National Taiwan University. She earned her Ph.D. in Medical Science from the University of Toronto under the mentorship of Dr. Minna Woo, where she was a three-time recipient of the Best Annual Trainee Award at the Banting and Best Diabetes Center. Following the postdoctoral training at the Joslin Diabetes Center from 2014 to 2020, she was promoted to Instructor in Medicine at Harvard Medical School. In April 2021, Dr. Cai joined the Lilly Diabetes Center of Excellence within the Indiana Biosciences Research Institute (IBRI) as an Assistant Investigator and was advanced to Scientific Director in 2025 before transitioning her research footprint to IUSM.
| Year | Degree | Institution |
|---|---|---|
| 2021 | Postdoctoral Training | Harvard Medical School |
| 2014 | PhD | University of Toronto |
| 2008 | M.Sc. | National Taiwan University |
| 2006 | BSC | Taipei Medical University |
Our research program integrates genetic engineering, cell biology, metabolism, and immunology to uncover the molecular mechanisms underlying pancreatic beta cell dysfunction, metabolic disorders, and autoimmune diabetes. Notably, our laboratory was the first group to successfully conduct in vivo CRISPR-Cas9 genome-wide screening in an autoimmune diabetes animal model. Utilizing a multidisciplinary approach, we combine genome-scale screening and CRISPRa gene-editing tools with human induced pluripotent stem cell differentiation platforms to investigate how modulating specific components of cellular bioprocesses can reduce beta cell immunogenicity and prevent cell death. Our active workflows bridge in vitro immune assays and in vivo autoimmune killing imaging with flow cytometry, immunostaining, and next-generation sequencing. Ultimately, our goal is to leverage these forward genetic insights to characterize novel targets regulating ER stress adaptation, protein secretion dynamics, mitochondrial bioenergetics, and cell survival, thereby advancing innovative beta cell replacement strategies and disease-modifying therapies for diabetes.
MacDonald Tara L, Ryback Birgitta, Aparecida da Silva Pereira Jéssica, Wei Siying, Mendez Bryhan, Cai Erica P, Ishikawa Yuki, Arbeau Meagan, Weir Gordon, Bonner-Weir Susan, Kissler Stephan, Yi Peng Molecular metabolism 2025 May
Li Jian, Lee Yu-Chi, Iessi Isabela L, Wu Chialing, Yi Peng, Cai Erica P STAR protocols 2023 Jun 16
Bode Kevin, MacDonald Tara, Stewart Taylor, Mendez Bryhan, Cai Erica P, Morrow Noelle, Lee Yu-Chi, Yi Peng, Kissler Stephan Diabetes 2023 Aug 01
Cai Erica P, Ishikawa Yuki, Zhang Wei, Leite Nayara C, Li Jian, Hou Shurong, Kiaf Badr, Hollister-Lock Jennifer, Yilmaz Nese Kurt, Schiffer Celia A, Melton Douglas A, Kissler Stephan, Yi Peng Nature metabolism 2020 Sep
Desc: New Investigator Gateway Award
Scope: National
Date: 2026-06-01
Desc: Career Development Award
Scope: International
Date: 2023-03-01